DALLAS, March 30, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain" market research report of 295 pages with latest updates, data and information to its online business intelligence library.
The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain" is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Spain. It identifies the key trends in the country's healthcare market, and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.
Austerity measures implemented by the Spanish government have negated the effect of key drivers behind the country's pharmaceutical market, resulting in a contracting market between 2008 and 2020.
Spain has strong healthcare infrastructure and the Spanish National Health System provides free healthcare for all citizens. In 2013, Spain spent approximately $17.4 billion on R&D, and exported approximately $13 billion of pharmaceuticals.
The pharmaceutical market was worth approximately $29 billion in 2008, and is projected to decline to approximately $22.6 billion by 2020, at a negative Compound Annual Growth Rate (CAGR) of 2.1%. The primary reasons for this decline are the austerity measures implemented by the Spanish government. The factors influencing the pharmaceutical market are -
- The increasingly elderly population
- Promotion of low-priced medicines
- Promotion of generics
- The medical device market was valued at $7.1 billion in 2008, and is projected to grow at a CAGR of 4.5% to an estimated $12 billion in 2020.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=105468 . (This is a premium report priced at US$1995 for a single user License.)
The report covers Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Roche, Novartis, Sanofi and GlaxoSmithKline, as well as profiles and SWOT analyses of the major players in the medical device market: Siemens Healthcare, Roche, Medtronic, Abbott Laboratories and DePuy
The in vitro diagnostics and diabetic care device segments were the largest contributors to Spain's medical device market in 2013. Other major segments included orthopedic, cardiovascular and ophthalmic devices. Spain's medical devices sector is benefiting significantly from the increase in electronic health services and a strong MedTech industry. However, new drug pricing policies and the promotion of generics as a cost-containment tool are severely limiting the country's pharmaceutical market growth.
GlobalData states that due to these strict regulations to contain costs by 2020, the Association Européenne des Spécialités Pharmaceutiques Grand Public (AESGP) reported a decline in Spain's pharmaceutical market revenues, from $29 billion in 2008 to $24 billion in 2013, at a negative CAGR of 3.7%. The market's value is expected to decrease even further to $22.6 billion by the end of the forecast period, representing a negative CAGR of 0.9%.
This report will enhance decision-making capability by allowing -
- Develop business strategies by understanding the trends shaping and driving the Spanish healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect the Spanish healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnerships
- Identify, understand, and capitalize on the opportunities and challenges in the Spanish healthcare market
Explore more reports on Healthcare at http://www.rnrmarketresearch.com/reports/life-sciences/healthcare .
More reports on Healthcare, Regulatory and Reimbursement Landscape:
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan
Japan's pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country's aging population. In 2013, Japan's population was approximately 127.2 million, having declined at a negative CAGR of 0.02% from 2008. Its public healthcare expenditure accounted for 82.8% of total healthcare expenditure, and the government spent approximately $14 billion on pharmaceutical R&D. Complete report available at http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-japan-market-report.html .
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - US
The population of the US in 2013 amounted to 316.1 million, having grown at a Compound Annual Growth Rate (CAGR) of 0.8% from 2008. The country's increasingly elderly population and corresponding increase in the incidence of chronic diseases will help to boost the growth of the pharmaceutical market, which was worth $326.9 billion in 2008, a value that is expected to have reached $548.4 billion by 2020 at a CAGR of 4.4%. Complete report available at http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-us-market-report.html .
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany
Germany's increasingly elderly population and its associated disease burden are key drivers of its pharmaceutical market. In 2013, the elderly accounted for 27.1% of the total population, expected to increase at Compound Annual Growth Rate (CAGR) of 1.2% to 29.5% in 2020. The pharmaceuticals market was worth $54.7 billion in 2008 and is projected to have reached a value of approximately $65 billion by 2020 at a CAGR of 1.4%. The German medical device market was valued at $18.9 billion in 2008 and is projected to grow at a CAGR of 5.1% to reach $34.4 billion in 2020. Complete report available at http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-germany-market-report.html .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research